Valeant strategy no panacea for US CLOs
Valeant Pharmaceuticals, the biggest obligor in US CLOs, is understood to be selling off assets in an attempt to pay down debt. But it may not be the shot in the arm the sector is after, writes Sam Kerr.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ European securitization issuance database
- ✔ Daily newsletters across markets and asset classes
- ✔ 1 weekly securitization podcast